Femoral BMD Change Following Cemented or Cementless Total Knee Arthroplasty

Description

The purpose of this study is to examine femur bone mineral density (BMD) change before and after surgery in patients receiving cemented or cementless total knee arthroplasty (TKA). performed with manual or robotic methods. 100 participants will be enrolled and can expect to be on study for up to 14 months.

Conditions

Knee Arthropathy

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to examine femur bone mineral density (BMD) change before and after surgery in patients receiving cemented or cementless total knee arthroplasty (TKA). performed with manual or robotic methods. 100 participants will be enrolled and can expect to be on study for up to 14 months.

Femoral Bone Mineral Density (BMD) Change Following Cemented or Cementless Total Knee Arthroplasty

Femoral BMD Change Following Cemented or Cementless Total Knee Arthroplasty

Condition
Knee Arthropathy
Intervention / Treatment

-

Contacts and Locations

Madison

UW School of Medicine and Public Health, Madison, Wisconsin, United States, 53792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients age greater than or equal to 55 years undergoing TKA with no prior total joint arthroplasty on the surgical side
  • * Normal BMD or osteopenia with Fracture Risk Assessment Tool (FRAX) not meeting Bone Health and Osteoporosis Foundation (BHOF) treatment recommendations, i.e., 10-year major osteoporotic fracture risk greater then or equal to 20 percent or hip fracture risk greater than or equal to 3 percent.
  • * Known clinical osteoporosis defined as any one of the following:
  • * Hip or spine T-score less than or equal to -2.5
  • * History of low trauma fracture after age 50
  • * FRAX fracture risk calculation greater than or equal to 20 percent for major osteoporotic fracture or greater than or equal to 3 percent for hip fracture
  • * Prior or current use of osteoporosis medications
  • * Current use of systemic glucocorticoids or bone-active medications
  • * Rheumatoid arthritis
  • * Laboratory abnormalities that in the opinion of study investigators may impact bone mineral density; including calcium, creatinine, albumin and parathyroid hormone (PTH)
  • * 25(OH)D less than 20 ng/mL
  • * Not suitable for study participation due to other reasons at the investigator's discretion

Ages Eligible for Study

55 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Brian Nickel, MD, PRINCIPAL_INVESTIGATOR, UW School of Medicine and Public Health

Study Record Dates

2026-12